BioCentury
ARTICLE | Company News

FDA approves Omeros' Omidria

June 3, 2014 2:04 AM UTC

FDA approved Omidria ( OMS302) from Omeros Corp. (NASDAQ:OMER) to maintain intraoperative mydriasis (pupil size) by preventing intraoperative miosis and to reduce postoperative ocular pain in patients undergoing cataract surgery or intraocular lens replacement surgery. Omeros said it plans to launch the product -- a combination of the anti-inflammatory agent ketorolac and the pupil dilating agent phenylephrine -- in the U.S. late this summer or in early fall, but declined to disclose pricing. Omidria is still under review in the EU, with a decision expected later this year. ...